← Back to Search

Antiplatelet Agent

Aspirin for Deep Vein Thrombosis

Phase 3
Waitlist Available
Led By Leslie Skeith, MD
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
i. Heterozygous factor V Leiden, or ii. Heterozygous prothrombin gene variant, or iii. Protein C deficiency, or iv. Protein S deficiency, and/or 2. Antepartum immobilization for ≥7 days. Immobilization is defined as bed rest with 90% of waking hours spent in bed at any time during the antepartum period AND/OR 1. Pre-pregnancy BMI ≥30 kg/m²
2. Smoking in the current pregnancy or within 3 months prior to pregnancy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 6 weeks and at 90 days
Awards & highlights

Summary

The goal of the PARTUM trial is to determine if taking low-dose aspirin daily for 6 weeks after delivery is similar (non-inferior) to usual care low-molecular-weight heparin injections to prevent venous thromboembolism (VTE: blood clots in the legs or lungs) for postpartum individuals with VTE risk factors.

Who is the study for?
The PARTUM trial is for individuals who have recently given birth and are at risk of developing blood clots. Participants must be in the postpartum period and meet certain criteria that put them at higher risk for venous thromboembolism.
What is being tested?
This study tests if taking low-dose aspirin daily for six weeks after giving birth can prevent blood clots as effectively as the standard treatment with low-molecular-weight heparin injections.
What are the potential side effects?
Possible side effects include bleeding risks associated with aspirin, such as bruising or nosebleeds, and potential injection site reactions or allergies from heparin.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 6 weeks and at 90 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 6 weeks and at 90 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Symptomatic VTE
Secondary study objectives
All-cause mortality
Clinically relevant non-major bleeding
Distal deep vein thrombosis
+8 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: AspirinExperimental Treatment1 Intervention
Low-dose aspirin (75-100 mg) once daily for 6 weeks.
Group II: Low-molecular-weight heparinActive Control1 Intervention
Site-specific low-molecular-weight heparin regimen as prescribed by the treating physician.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Aspirin
2014
Completed Phase 4
~55580

Find a Location

Who is running the clinical trial?

University of CalgaryLead Sponsor
805 Previous Clinical Trials
875,702 Total Patients Enrolled
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,371 Previous Clinical Trials
26,510,969 Total Patients Enrolled
11 Trials studying Deep Vein Thrombosis
9,434 Patients Enrolled for Deep Vein Thrombosis
Leslie Skeith, MDPrincipal InvestigatorUniversity of Calgary
3 Previous Clinical Trials
1,083 Total Patients Enrolled
~5870 spots leftby Aug 2030
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top